- SS Innovations reported record first-quarter 2026 revenue of $11.1 million, up 116.8% year over year, driven by growing adoption of its SSi Mantra surgical robotic system.
- The installed base reached 194 SSi Mantra systems across 11 countries, with nearly 9,750 cumulative robotic procedures completed.
- Regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines, expanded the company’s international market access during the quarter.
- SS Innovations recently completed the world’s longest-distance robotic cardiac telesurgery in history, demonstrating the capabilities of its remote surgery platform.
- The company continues pursuing regulatory clearance in both the United States and Europe while expanding its presence in emerging healthcare markets.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies to aid in cardiac and other surgeries, including telesurgeries, reported record first-quarter 2026 financial results, highlighting accelerating commercial adoption of its SSi Mantra surgical robotic platform as the company continues expanding internationally and pursuing regulatory approvals in major healthcare markets.
According to the company’s first-quarter earnings announcement, revenue increased 116.8% year over year to $11.1 million, driven primarily by higher installations of the SSi Mantra surgical robotic system and increased procedure volumes. Gross profit rose to $5.3 million from $1.1 million a year earlier, while gross margin expanded to 48.0%, reflecting greater operating scale and manufacturing efficiency (https://ibn.fm/z0I6H).
The company also reported continued improvement in its financial position, ending the quarter with approximately $16 million in cash and cash equivalents and no long-term debt. Earlier this year, the company completed a private placement that generated approximately $18.6 million in gross proceeds to support future growth initiatives.
During the quarter, SS Innovations installed 26 additional SSi Mantra systems, representing a 73% increase compared with the first quarter of 2025. As of March 31, the company’s installed base had grown to 194 systems operating across eleven countries. Clinical utilization also continued to increase. The company reported that surgeons have now completed 9,744 procedures using the SSi Mantra platform, including 482 cardiac surgeries, 161 pediatric procedures and 157 telesurgeries.
Chief Executive Officer Dr. Sudhir Srivastava said the results reflected growing acceptance of the platform among hospitals and physicians, citing its combination of advanced robotic capabilities, ease of use, integrated training features, and lower cost relative to many established robotic surgery systems.
The first quarter also brought several regulatory milestones. SS Innovations received approval for the SSi Mantra system in Sri Lanka and Kenya while Indonesia and the Philippines authorized the platform for telesurgery applications. Those approvals form part of the company’s broader strategy to expand access to robotic surgery in regions where healthcare providers have historically faced financial barriers to adopting robotic technologies.
The company is also working toward entry into larger regulated markets. Management expects the U.S. Food and Drug Administration to complete review of its 510(k) submission during 2026 while continuing efforts to obtain CE Mark certification for the European Union. “Looking ahead, we aim to fortify our position as a leader in the substantial Indian market, expand our global footprint in underserved countries, and secure entry into the United States and European Union markets,” Dr. Srivastava said. “We are very excited about the growth runway ahead and remain steadfast in our commitment to democratizing access to advanced surgical robotic care.”
More recently, SS Innovations attracted attention with another striking demonstration of its telesurgery capabilities. In early June, the company announced the successful completion of what it described as the world’s longest-distance robotic telesurgery, performed over approximately 12,500 miles (20,000 kilometers) between Guyana and India (https://ibn.fm/2wm2B).
The cardiac operation was performed by Dr. Srivastava, operating remotely from Guyana in South America, using the company’s portable SSi MantrAsana tele-surgeon console. Robotic equipment positioned with the patient in India replicated the surgeon’s delicate movements in real time while operating across an international fiber-optic network. The procedure involved a cardiac operation known as a Left Internal Mammary Artery (“LIMA”) takedown. According to the company, the system operated with network latency of approximately 290 to 300 milliseconds while maintaining surgical precision.
Although telesurgery currently represents a relatively small portion of the company’s overall commercial applications, management views the technology as an important long-term opportunity for expanding access to specialized surgical expertise in many remote and underserved regions. To date, SS Innovations reports that 173 robotic telesurgeries have been completed using the SSi Mantra platform, including 22 cardiac telesurgeries. According to the company, the SSi Mantra remains the only robotic surgical system that has been used for robotic cardiac telesurgery.
The company’s broader business remains centered on hospital adoption of robotic systems to aid in a wide variety of surgeries. The SSi Mantra platform is designed as a modular robotic surgery system capable of supporting three to five robotic arms, depending on procedural requirements. The system includes an open-console surgeon workstation, three-dimensional 4K visualization, integrated imaging capabilities, and a growing portfolio of more than 40 robotic surgical instruments supporting multiple specialties.
Unlike many robotic surgery platforms initially focused on a narrow range of procedures, the SSi Mantra has been clinically validated across more than 170 surgical procedures in India, including general surgery, gynecology, urology, thoracic surgery, cardiac surgery, pediatric procedures and ear, nose and throat operations.
The company’s strategy emphasizes affordability alongside functionality. By developing a lower-cost robotic platform, SS Innovations aims to broaden adoption among hospitals that have traditionally found robotic surgery systems financially difficult to acquire. That approach may be particularly relevant across emerging healthcare markets, where demand for minimally invasive surgery continues to grow while healthcare budgets remain constrained.
For more information, visit the company’s website at www.SSInnovations.com.
Update:
As of June 22, 2026, the cumulative number of multi-specialty procedures completed with the SSi Mantra surgical robotic system totaled 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Additionally, approximately 2,100 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of procedures.
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
